{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:23:07Z","timestamp":1794741787033,"version":"4.9.1"},"reference-count":52,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK selectivity. This analysis characterizes pooled CV adverse events (AE) data in patients with CLL who received acalabrutinib monotherapy in clinical trials (clinicaltrials gov. Identifier: NCT02029443, NCT02475681, NCT02970318 and NCT02337829). Acalabrutinib was given orally at total daily doses of 100\u2013400 mg, later switched to 100 mg twice daily, and continued until disease progression or toxicity. Data from 762 patients (median age: 67 years [range, 32\u201389]; median follow-up: 25.9 months [range, 0\u201358.5]) were analyzed. Cardiac AE of any grade were reported in 129 patients (17%; grade \u22653, n=37 [5%]) and led to treatment discontinuation in seven patients (1%). The most common any-grade cardiac AE were atrial fibrillation\/flutter (5%), palpitations (3%), and tachycardia (2%). Overall, 91% of patients with cardiac AE had CV risk factors before acalabrutinib treatment. Among 38 patients with atrial fibrillation\/flutter events, seven (18%) had prior history of arrhythmia or atrial fibrillation\/flutter. Hypertension AE were reported in 67 patients (9%), 43 (64%) of whom had a preexisting history of hypertension; no patients discontinued treatment due to hypertension. No sudden cardiac deaths were reported. Overall, these data demonstrate a low incidence of new-onset cardiac AE with acalabrutinib in patients with CLL. Findings from the head-to-head, randomized trial of ibrutinib and acalabrutinib in patients with highrisk CLL (clinicaltrials gov. Identifier: NCT02477696) prospectively assess differences in CV toxicity between the two agents.<\/jats:p>","DOI":"10.3324\/haematol.2021.278901","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T03:39:17Z","timestamp":1632973157000},"page":"1335-1346","source":"Crossref","is-referenced-by-count":57,"title":["Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients"],"prefix":"10.3324","volume":"107","author":[{"given":"Jennifer R.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Kuptsova-Clarkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"36634","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma version 4.2021. 2021."},{"key":"36635","unstructured":"Imbruvica [package insert]. 2020."},{"key":"36636","unstructured":"Calquence [package insert]. 2019."},{"key":"36637","unstructured":"Brukinsa [package insert]. 2019."},{"key":"36638","doi-asserted-by":"crossref","unstructured":"Vitale C, Burger JA. Chronic lymphocytic leukemia therapy: new targeted therapies on the way. Expert Opin Pharmacother. 2016; 17(8):1077-1089.","DOI":"10.1517\/14656566.2016.1168401"},{"key":"36639","doi-asserted-by":"crossref","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018; 17(1):57.","DOI":"10.1186\/s12943-018-0779-z"},{"key":"36640","doi-asserted-by":"crossref","unstructured":"Barf T, Covey T, Izumi R. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017; 363(2):240-252.","DOI":"10.1124\/jpet.117.242909"},{"key":"36641","doi-asserted-by":"crossref","unstructured":"Tam CS, Trotman J, Opat S. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019; 134(11):851-859.","DOI":"10.1182\/blood.2019001160"},{"key":"36642","doi-asserted-by":"crossref","unstructured":"Byrd JC, Harrington B, O'Brien S. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374(4):323-332.","DOI":"10.1056\/NEJMoa1509981"},{"key":"36643","doi-asserted-by":"crossref","unstructured":"Bond DA, Woyach JA. Targeting BTK in CLL: beyond Ibrutinib. Curr Hematol Malig Rep. 2019; 14(3):197-205.","DOI":"10.1007\/s11899-019-00512-0"},{"key":"36644","doi-asserted-by":"crossref","unstructured":"Kaptein A, de Bruin G, Emmelot-van Hoek M. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood. 2018; 132(Supplement 1):1871.","DOI":"10.1182\/blood-2018-99-109973"},{"key":"36645","doi-asserted-by":"crossref","unstructured":"Salem JE, Manouchehri A, Bretagne M. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019; 74(13):1667-1678.","DOI":"10.1016\/j.jacc.2019.07.056"},{"key":"36646","doi-asserted-by":"crossref","unstructured":"Brown JR, Moslehi J, O'Brien S. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017; 102(10):1796-1805.","DOI":"10.3324\/haematol.2017.171041"},{"key":"36647","doi-asserted-by":"crossref","unstructured":"Dickerson T, Wiczer T, Waller A. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019; 134(22):1919-1928.","DOI":"10.1182\/blood.2019000840"},{"key":"36648","doi-asserted-by":"crossref","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019; 14(2):e0211228.","DOI":"10.1371\/journal.pone.0211228"},{"key":"36649","doi-asserted-by":"crossref","unstructured":"Byrd JC, Brown JR, O'Brien S. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213-223.","DOI":"10.1056\/NEJMoa1400376"},{"key":"36650","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hillmen P, O'Brien S. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019; 133(19):2031-2042.","DOI":"10.1182\/blood-2018-08-870238"},{"key":"36651","doi-asserted-by":"crossref","unstructured":"Burger JA, Tedeschi A, Barr PM. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373(25):2425-2437.","DOI":"10.1056\/NEJMoa1509388"},{"key":"36652","doi-asserted-by":"crossref","unstructured":"Byrd JC, Furman RR, Coutre SE. Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase 1b\/2 PCYC-1102 study. Clin Cancer Res. 2020; 26(15):3918-3927.","DOI":"10.1158\/1078-0432.CCR-19-2856"},{"key":"36653","doi-asserted-by":"crossref","unstructured":"Langerbeins P, Bahlo J, Rhein C. Ibrutinib versus placebo in patients with asymptomatic, treatment-na\u00efve early stage CLL: primary endpoint results of the phase 3 double-blind randomized CLL12 trial. Hematol Oncol. 2019; 37(suppl 2):38-40.","DOI":"10.1002\/hon.7_2629"},{"key":"36654","doi-asserted-by":"crossref","unstructured":"Ganatra S, Sharma A, Shah S. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018; 4(12):1491-1500.","DOI":"10.1016\/j.jacep.2018.06.004"},{"key":"36655","doi-asserted-by":"crossref","unstructured":"Jones J, George BS, Peterson CB. Hypertension, cardiovascular and renal complications observed in patients with chronic lymphocytic leukemia receiving long-term therapy with ibrutinib. Blood. 2020; 136(Supplement 1):27-28.","DOI":"10.1182\/blood-2020-141284"},{"key":"36656","doi-asserted-by":"crossref","unstructured":"Sharman JP, Egyd M, Jurczak W. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395(10232):1278-1291.","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"36657","doi-asserted-by":"crossref","unstructured":"Ghia P, Pluta A, Wach M. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020; 38(25):2849-2861.","DOI":"10.1200\/JCO.19.03355"},{"key":"36658","doi-asserted-by":"crossref","unstructured":"Byrd JC, Furman RR, Coutre SE. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42.","DOI":"10.1056\/NEJMoa1215637"},{"key":"36659","doi-asserted-by":"crossref","unstructured":"Byrd JC, Wierda WG, Schuh A. Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020; 135(15):1204-1213.","DOI":"10.1182\/blood.2018884940"},{"key":"36660","doi-asserted-by":"crossref","unstructured":"Awan FT, Schuh A, Brown JR. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019; 3(9):1553-1562.","DOI":"10.1182\/bloodadvances.2018030007"},{"key":"36661","doi-asserted-by":"crossref","unstructured":"Byrd JC, Woyach JA, Furman RR. Acalabrutinib in treatment-naive (TN) chronic lymphocytic leukemia (CLL): updated results from the phase 1\/2 ACE-CL-001 study. Blood. 2018; 132(Suppl 1):S692.","DOI":"10.1182\/blood-2018-99-110451"},{"key":"36662","doi-asserted-by":"crossref","unstructured":"Sun CCL, Nierman PK, Kendall EK. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020; 136(1):93-105.","DOI":"10.1182\/blood.2019003715"},{"key":"36663","doi-asserted-by":"crossref","unstructured":"Archibald WJ, Rabe KG, Kabat BF. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. 2021; 100(1):143-155.","DOI":"10.1007\/s00277-020-04094-3"},{"key":"36664","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Parikh SA, Noseworthy PA. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017; 58(7):1630-1639.","DOI":"10.1080\/10428194.2016.1257795"},{"key":"36665","doi-asserted-by":"crossref","unstructured":"Farooqui M, Valdez J, Soto S, Bray A, Tian X, Wiestner A. Atrial fibrillation in CLL\/SLL patients on ibrutinib. Blood. 2015; 126(23):2933.","DOI":"10.1182\/blood.V126.23.2933.2933"},{"key":"36666","doi-asserted-by":"crossref","unstructured":"Burger JA, Barr PM, Robak T. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020; 34(3):787-798.","DOI":"10.1038\/s41375-019-0602-x"},{"key":"36667","doi-asserted-by":"crossref","unstructured":"Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016; 375(15):1457-1467.","DOI":"10.1056\/NEJMra1100265"},{"key":"36668","doi-asserted-by":"crossref","unstructured":"Lampson BL, Yu L, Glynn RJ. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017; 129(18):2581-2584.","DOI":"10.1182\/blood-2016-10-742437"},{"key":"36669","doi-asserted-by":"crossref","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014; 124(25):3829-3830.","DOI":"10.1182\/blood-2014-10-604272"},{"key":"36670","doi-asserted-by":"crossref","unstructured":"Xiao L, Salem JE, Clauss S. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020; 142(25):2443-2455.","DOI":"10.1161\/CIRCULATIONAHA.120.049210"},{"key":"36671","doi-asserted-by":"crossref","unstructured":"Patel V, Balakrishnan K, Bibikova E. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017; 23(14):3734-3743.","DOI":"10.1158\/1078-0432.CCR-16-1446"},{"key":"36672","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hillmen P, Ghia P. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase 3 trial. J Clin Oncol. 2021 Jul 26. 2021; 39(31):3441-3452.","DOI":"10.1200\/JCO.21.01210"},{"key":"36673","unstructured":"Win NT, Teo SP. Atrial fibrillation in older patients-reducing stroke risk is not only about anticoagulation. J Geriatr Cardiol. 2016; 13(10):880-882."},{"key":"36674","doi-asserted-by":"crossref","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8):983-988.","DOI":"10.1161\/01.STR.22.8.983"},{"key":"36675","doi-asserted-by":"crossref","unstructured":"Verma A, Kalman JM, Callans DJ. Treatment of patients with atrial fibrillation and heart failure with reduced ejection fraction. Circulation. 2017; 135(16):1547-1563.","DOI":"10.1161\/CIRCULATIONAHA.116.026054"},{"key":"36676","doi-asserted-by":"crossref","unstructured":"Chatterjee NA, Chae CU, Kim E. Modifiable risk factors for incident heart failure in atrial fibrillation. JACC Heart Fail. 2017; 5(8):552-560.","DOI":"10.1016\/j.jchf.2017.04.004"},{"key":"36677","doi-asserted-by":"crossref","unstructured":"January CT, Wann LS, Calkins H. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019; 140(2):e125-e151.","DOI":"10.1161\/CIR.0000000000000665"},{"key":"36678","doi-asserted-by":"crossref","unstructured":"January CT, Wann LS, Alpert JS. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23):2071-2104.","DOI":"10.1161\/CIR.0000000000000040"},{"key":"36679","doi-asserted-by":"crossref","unstructured":"Hindricks G, Potpara T, Dagres N. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5):373-498.","DOI":"10.1093\/eurheartj\/ehaa945"},{"key":"36680","doi-asserted-by":"crossref","unstructured":"Siontis KC, Gersh BJ, Killian JM. Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. Heart Rhythm. 2016; 13(7):1418-1424.","DOI":"10.1016\/j.hrthm.2016.03.003"},{"key":"36681","doi-asserted-by":"crossref","unstructured":"Barr PM, Robak T, Owen C. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018; 103(9):1502-1510.","DOI":"10.3324\/haematol.2018.192328"},{"key":"36682","doi-asserted-by":"crossref","unstructured":"O'Brien S, Hillmen P, Coutre S. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018; 18(10):648-657.","DOI":"10.1016\/j.clml.2018.06.016"},{"key":"36683","doi-asserted-by":"crossref","unstructured":"Coutre SE, Byrd JC, Hillmen P. Long-term safety of singleagent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019; 3(12):1799-1807.","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"36684","doi-asserted-by":"crossref","unstructured":"Moslehi J. The cardiovascular perils of cancer survivorship. N Engl J Med. 2013; 368(11):1055-1056.","DOI":"10.1056\/NEJMe1215300"},{"key":"36685","doi-asserted-by":"crossref","unstructured":"Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cardiovascular surveillance. N Engl J Med. 2013; 369(19):1779-1781.","DOI":"10.1056\/NEJMp1313140"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278901\/73751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278901\/74528","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10414\/73751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:26Z","timestamp":1794045626000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.278901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.278901","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}